Pharmaceutical Investing Foamix Announces FDA Acceptance of New Drug Application for FMX101 Minocycline Foam to Treat Moderate-to-Severe Acne
Juggernaut Announces Strategic Investment by Crescat Capital Funds for 28.95% Ownership - Dr. Quinton Hennigh Technical Advisor
